Gain Therapeutics, Inc. (GANX) shareholders
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GANX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Marshall Wace, Llp | 1,923,546 | 4.41% | $3.90M | +153,758 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 1,137,290 | 2.61% | $2.31M | +568,645 | 0.00% |
| Potomac Capital Management, Inc. | 946,400 | 2.17% | $1.92M | −62,200 | 1.31% |
| Gsa Capital Partners Llp | 632,131 | 1.45% | $1.28M | +319,664 | 0.08% |
| Jones Financial Companies Lllp | 608,592 | 1.39% | $1.07M | −23,023 | 0.00% |
| DME Capital Management, LP | 566,130 | 1.30% | $1.15M | – | 0.03% |
| Vanguard Capital Management LLC | 480,269 | 1.10% | $974.95K | +80,383 | 0.00% |
| Geode Capital Management, LLC | 453,501 | 1.04% | $921.37K | +6,159 | 0.00% |
| BlackRock, Inc. | 274,957 | 0.63% | $558.16K | +49,911 | 0.00% |
| Vanguard Fiduciary Trust Co | 231,534 | 0.53% | $470.01K | +1,555 | 0.00% |
| UBS Group AG | 215,012 | 0.49% | $436.48K | −5,477 | 0.00% |
| Stratos Wealth Partners, LTD. | 200,000 | 0.46% | $406.00K | +68,379 | 0.00% |
| Cresset Asset Management, LLC | 160,000 | 0.37% | $324.80K | – | 0.00% |
| State Street Corp | 157,537 | 0.36% | $319.80K | – | 0.00% |
| Citadel Advisors LLC | 154,524 | 0.35% | $313.68K | +129,624 | 0.00% |
| Squarepoint Ops LLC | 136,359 | 0.31% | $276.81K | New | 0.00% |
| Morgan Stanley | 125,972 | 0.29% | $255.72K | −13,680 | 0.00% |
| LPL Financial LLC | 117,251 | 0.27% | $238.02K | +13,000 | 0.00% |
| Northern Trust Corp | 97,013 | 0.22% | $196.94K | −16,984 | 0.00% |
| Susquehanna International Group, Llp | 78,206 | 0.18% | $158.76K | −353,061 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 50 | 9M | 21.1% | 12 / 15 | 9 / 4 | 2M | 1M |
| Q1 2026 | 42 | 8M | 18.8% | 10 / 9 | 10 / 15 | 2M | 1M |
| Q4 2025 | 48 | 8M | 18.5% | 21 / 15 | 3 / 10 | 5M | 1M |
| Q3 2025 | 38 | 4M | 10.0% | 9 / 14 | 4 / 6 | 1M | 0M |
| Q2 2025 | 35 | 4M | 8.7% | 6 / 11 | 5 / 4 | 1M | 0M |
| Q1 2025 | 33 | 3M | 6.4% | 10 / 12 | 2 / 2 | 1M | 0M |
| Q4 2024 | 25 | 2M | 4.5% | 10 / 8 | 2 / 4 | 1M | 0M |
| Q3 2024 | 19 | 2M | 3.8% | 3 / 5 | 4 / 11 | 1M | 2M |
| Q2 2024 | 28 | 3M | 7.0% | 8 / 9 | 7 / 6 | 2M | 1M |
| Q1 2024 | 26 | 2M | 4.3% | 6 / 11 | 6 / 3 | 1M | 0M |
| Q4 2023 | 24 | 2M | 3.5% | 3 / 8 | 6 / 3 | 0M | 0M |
| Q3 2023 | 24 | 2M | 3.5% | 2 / 9 | 6 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
12 funds held GANX in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of GANX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 430,902 | 0.99% | $874.73K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 207,106 | 0.47% | $403.86K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 144,159 | 0.33% | $292.64K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 57,335 | 0.13% | $111.80K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 55,636 | 0.13% | $108.49K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 30,004 | 0.07% | $60.91K | 0.04% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 28,629 | 0.07% | $55.83K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 9,730 | 0.02% | $19.75K | 0.01% | Jun 30, 2026 |
| Total Stock Market Index Trust | 966 | 0.00% | $1.96K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -7,200 | -0.02% | -$14.62K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gene Mack | CEO, President, Director | 14,400 | 0.03% | Mar 26, 2026 |
| Jeanette Weidner | See Remarks | – | – | Oct 30, 2026 |
| Gianluca Fuggetta | See Remark | – | – | Mar 26, 2026 |
| Dov A. Goldstein Md | Director | – | – | Jul 17, 2026 |
| Hans Peter Hasler | Director | – | – | Jul 17, 2026 |
| Claude Nicaise | Director | – | – | Jul 17, 2026 |
| Jeffrey Scott Riley | Director | 30,000 | 0.07% | Jul 17, 2026 |
| Gwen A. Melincoff | Director | – | – | Jul 17, 2026 |
| Khalid Islam | Director | 930,784 | 2.13% | Jul 17, 2026 |
| Eric I. Richman | Director | 304,458 | 0.70% | Jun 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gene Mack CFO and Interim CEO | Aug 9, 2024 | Buy | +14,400 | $1.01 | $14.54K | 14,400 |
| Khalid Islam Executive Chairman, Director | Aug 9, 2024 | Buy | +50,000 | $1.00 | $50.00K | 50,000 |
| Eric I. Richman Director | Jul 1, 2024 | Buy | +12,000 | $1.21 | $14.52K | 289,629 |
| Eric I. Richman Director | Jul 1, 2024 | Buy | +5,000 | $1.23 | $6.15K | 277,629 |
| Jeffrey Scott Riley Director | Mar 28, 2024 | Buy | +30,000 | $3.86 | $115.80K | 30,000 |
| Matthias Alder Chief Executive Officer, Director | Mar 26, 2024 | Option exercise | +637 | – | – | 27,225 |
| Matthias Alder Chief Executive Officer, Director | Mar 26, 2024 | Option exercise | +18,750 | – | – | 25,763 |
| Matthias Alder Chief Executive Officer, Director | Mar 26, 2024 | Option exercise | +825 | – | – | 26,588 |
| Matthias Alder Chief Executive Officer, Director | Mar 26, 2024 | Tax withholding | −6,085 | $4.06 | $24.71K | 21,140 |
| Matthias Alder Chief Executive Officer, Director | Dec 21, 2023 | Sale | −206 | $2.46 | $507 | 5,286 |
| Matthias Alder Chief Executive Officer, Director | Dec 20, 2023 | Option exercise | +637 | – | – | 5,492 |
| Matthias Alder Chief Executive Officer, Director | Dec 7, 2023 | Sale | −1,820 | $2.50 | $4.55K | 4,855 |
| Matthias Alder Chief Executive Officer, Director | Oct 1, 2023 | Option exercise | +825 | – | – | 6,675 |
| Matthias Alder Chief Executive Officer, Director | Sep 20, 2023 | Option exercise | +2,550 | – | – | 5,850 |
| Eric I. Richman Director | Sep 20, 2023 | Option exercise | +54,900 | – | – | 272,629 |
| Matthias Alder Chief Executive Officer, Director | Jul 1, 2023 | Option exercise | +3,300 | – | – | 3,300 |
| Eric I. Richman CHIEF EXECUTIVE OFFICER, Director | May 25, 2022 | Buy | +2,482 | $2.58 | $6.40K | 217,729 |
| Eric I. Richman CHIEF EXECUTIVE OFFICER, Director | May 20, 2022 | Buy | +9,256 | $2.83 | $26.19K | 215,247 |
| Eric I. Richman CHIEF EXECUTIVE OFFICER, Director | May 19, 2022 | Buy | +4,000 | $2.71 | $10.84K | 205,991 |
| Salvatore Calabrese CHIEF FINANCIAL OFFICER | May 19, 2022 | Buy | +3,000 | $2.70 | $8.10K | 3,000 |
| Salvatore Calabrese CHIEF FINANCIAL OFFICER | May 19, 2022 | Buy | +3,000 | $8100.00 | $24.30M | – |
| Eric I. Richman Chief Executive Officer, Director | Aug 16, 2021 | Buy | +4,922 | $7.87 | $38.74K | 216,820 |
| Eric I. Richman Director | Aug 16, 2021 | Option exercise | +4,922 | $7.87 | $38.74K | 216,820 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Gain Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,043 shares on Oct 7, 2026 over the last 90 days.
See a number that looks wrong?